Jonathan J. Darrow

Brigham and Women's Hospital — United States

Economics, Econometrics and Finance · Social Sciences

21h-index2.4kcitations122works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmaceutical Economics and Policy(61), Health Systems, Economic Evaluations, Quality of Life(55), Pharmaceutical industry and healthcare(20), Pharmaceutical studies and practices(20), Biomedical Ethics and Regulation(19)

Publications122 total

Physician Perspectives on Real-World Evidence for Prescribing to Older Patients
Journal of Pharmacy Practice·2026
Statutory Thickets and Drug Shortages: Accumulating Legislation as an Underlying Cause
American Journal of Law & Medicine·2025
Incremental therapeutic value of FDA-designated “breakthrough” drugs based on ratings from four international organizations: a cross-sectional study
Journal of Pharmaceutical Health Services Research·2025Open Access
Reconsidering Eradication to Address the Global Infectious Disease Burden
SSRN Electronic Journal·2025· 1 citedOpen Access
Telomeres: The Promise of New Cancer Therapies
American Journal of Molecular Biology·2025Open Access
Impostor Syndrome: Fraudulent Participants in Qualitative Research Can Skew Results
The Journal of Law Medicine & Ethics·2025· 1 cited
Physician-Patient Communication about Novel Drugs and High-Risk Medical Devices
Medical Decision Making·2024· 1 citedOpen Access
Vaccine Messaging by the FDA: A National Randomized Survey Study
Journal of General Internal Medicine·2024Open Access
The prevalence of post-NDA drug patents and their relationship to the timing of generic approval
Nature Biotechnology·2024· 1 cited
Patient perspectives on evidence supporting drug safety and effectiveness: “What does it mean for me?”
Journal of the American Geriatrics Society·2024· 1 citedOpen Access
Trust in the Food and Drug Administration: A National Survey Study
Clinical Pharmacology & Therapeutics·2024· 9 citedOpen Access
Leah Z. Rand, Daniel P. Carpenter, Aaron S. Kesselheim, Anushka Bhaskar, Jonathan J. Darrow, and William B. Feldman Reply
The Hastings Center Report·2024Open Access
CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations
Journal of Law and the Biosciences·2024· 14 citedOpen Access
Physicians’ Perspectives On FDA Regulation Of Drugs And Medical Devices: A National Survey
Health Affairs·2024· 20 cited
Prioritizing Early Disease Intervention
Therapeutic Innovation & Regulatory Science·2023
Securing the Trustworthiness of the FDA to Build Public Trust in Vaccines
The Hastings Center Report·2023· 5 citedOpen Access
Variation in Endpoints in FDA Medication Approvals
Neurology·2023· 3 citedOpen Access
An Empirical Review of Key Glucose Monitoring Devices: Product Iterations and Patent Protection
Journal of Diabetes Science and Technology·2023· 5 citedOpen Access
Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease
Clinical Pharmacology & Therapeutics·2023· 6 citedOpen Access
Trust and Regulation: Assuring Scientific Independence in the FDA's Emergency Use Authorization Process
Journal of Health Politics Policy and Law·2023· 4 cited
page 1 of 7Next →

Frequent Co-authors

Aaron S. Kesselheim(38), Jerry Avorn(12), Beatrice L. Brown(6), Reed F. Beall(6), Mayookha Mitra-Majumdar(5), Ameet Sarpatwari(4), Catherine Pham(4), Sanket S. Dhruva(4), Rita F. Redberg(4), Thomas J. Hwang(3), Osman Moneer(3), Krysten W. Joyce(3), Murray N. Ross(3), Jessica M. Franklin(2), Bishal Gyawali(2), Lisette Pregelj(2), Damian Hine(2), Zhigang Lu(2), Timo Minssen(2), Michael S. Sinha(2)